From the animal feed to the meat and milk, exceeding of the borders in the bags of soy beans and corn and hides itself in a multiplicity of products, also in the celebrated " Bio Produkte" , if we believe the words - they are the genetically changed organisms, GVO, against which we are rather helpless, and briefly them to penetrate knew even drugs. Disputed Biopharming Now, that is no more novelty, but " for the common people, according to the article recently in the Italian newspaper; L' Espresso" to do, a quantity of research institutes in the whole world the last 20 year published the so-called " Biopharming " - Production of drugs with the help of genetically changed plants, those of the inviting prospect on savings in billion height set in motion. Also the European Union has 12.000.000 € for PharmaPlanta, public-private consortium, which covers 12 countries, and which the clinical test phase began in the year 2009 assigned. genetically did curse or benediction change organisms GVO? Vaccine breakfast According to Mario Pezzotti, professor for genetics at the faculty for agrarian sciences and technology at the University of Verona, Italy, Biopharming now a turning point reached. " With the 90's we examined the possibility of the production of bananas, tomatoes or potatoes around vaccine contained changed. In the course of the time however we recognized the fact that this idea became rather naive, because is e.g. it is nearly impossible the children with standard-therapeutic dose of a vaccine or an active substance feed. Thus we concentrated on the chances of the increasing cleaned substances offered, and got ourselves for a multiplicity of possible applications, from those some from now on in clinical test phases. " The potential of this alternative was proven also developed of the experimental vaccine against several kinds of cancer in the year 2008 and basedly on tobacco plants, by a team of US scientist, the study in question places themselves in proceedings OF the national Academy OF Sciences (PNAS publishes). From researchers the Stanford University under the direction of Ronald Levy antibody collected from 16 patients of the lymphoma, they transferred, use a team into the tobacco virus, in order to infect tobacco plants, to for its part own antibodies produced in large quantities. Then these antibodies were cleaned and given patients, thus one a very strong reaction of the stimulation of the immune system for approximately 70% of the patients. The study in question is now regarded as a kind sign for one of the most promising sectors of the Biopharming Design: the personalisierte therapies against cancer and beyond that. In addition Bavarian - one of the companies, which took at the study part - transferred recently one of the most modern Biotech enterprises in the industry, icon Genetics. The reason? Everything is possible by Biopharming: They know vaccines, monoclonal antibodies, enzymes, to receive medicines. And above all, then you do this with substantially smaller costs compared with those from the present systems received. Around humans a conception of the sums on the play, a further study in the technical periodical " Nature Biotechnology" one published the following estimate: always a gram of Avastin, monoclonal antibody for the treatment of different kinds of cancer certified, the costs of the manufacturers 150 $ with animal cell cultures and only 0.05 $ by plants. And according to some estimations becomes worth the Biopharming market over 100 billion dollar in the year 2020.
